Summary

Overview
The Global Inter-alpha-inhibitor Proteins Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Inter-alpha-inhibitor proteins (IAIPs) are a family of glycoproteins that are crucial to numerous physiological and pathological processes in the human body. These proteins, which are made up of many subunits, control inflammation, tissue repair, and other essential biological processes.
Inter-inhibitor (IAI), which has a molecular weight of 250 kDa and is made up of two heavy chains and one light chain, and pre-inhibitor (PAI), which has a molecular weight of 125 kDa and is made up of one heavy chain and one light chain, are the two main types that are present in human plasma.
Market Dynamics: Drivers
The Increasing Focus on Inflammatory Diseases
Even in the current era of critical care management, sepsis continues to be a serious issue with high morbidity and death. It is linked to organ dysfunction that poses a serious risk of death as a result of improper host reactions to infection. Neutrophils have long been thought to as innate immune system effector cells with a limited ability for metabolic activity. Neutrophils are primarily responsible for acute inflammation and resistance to external infections.
Increased activity of neutrophil-derived serine proteases, such as leukocyte elastase and cathepsin G, has been shown by experimental and clinical data to play a significant role in sepsis-related tissue injury. In order to reestablish the equilibrium between proteases and protease inhibitors in sepsis, the administration of protease inhibitors has been suggested as a treatment method.
The inter-inhibitor protein (IAIP) family is one such inhibitor. It is a class of serine protease inhibitors that is present in human plasma in relatively high amounts (300–600 g/mL). IAIPs are made up of glycosaminoglycan chains that are covalently connected by heavy- and light-chain polypeptide subunits.
The serine protease inhibitory action can be found in the light chain, also known as bikunin. Patients with inflammatory conditions such as pancreatitis, shock, and disseminated intravascular coagulation (DIC) frequently utilize the medication bikunin.
Limited Clinical Data
Although there may be insufficient clinical evidence to support IAIPs' efficacy and safety in some applications, their therapeutic and diagnostic potential is still being investigated. This dearth of reliable clinical data may operate as a barrier. IAIP production can be difficult to scale, and it can be complicated. Meeting market demand may be hampered by the challenge of maintaining constant quality and production of these proteins.
Segment Analysis
The global inter-alpha-inhibitor proteins market is segmented based on phases, molecule type, and region.
The early-stage product (Phase I) segment accounted for approximately 52.5% of the market share
The increasing research activities drive the segment in the market. For instance, in April 2020, ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for the treatment of acute inflammatory conditions. Early studies have shown that this IAIP technology may provide a highly novel, disease-modifying treatment for a variety of acute inflammatory disorders. Dysregulated inflammation plays a significant part in the pathophysiology of such illnesses, and there are currently no viable therapies.
IAIP is blood-circulating, naturally occurring proteins that have been demonstrated via extensive research at ProThera to be crucial to maintaining human health by reducing inflammation. They have the potential to alter the paradigm of treatment for individuals with dysregulated immune responses as they exert their anti-inflammatory actions through a variety of routes. The amounts of these anti-inflammatory proteins, however, sharply decrease during acute infections. Many preclinical research support a replenishing strategy for patients on Inter-alpha Inhibitors.
Geographical Analysis
North America segment accounted for approximately 41.2% of the market share
North America has been a dominant force in the global Inter-alpha-inhibitor Proteins market. Two gastrointestinal conditions that fall under the category of inflammatory bowel disease (IBD) are Crohn's disease and ulcerative colitis. Irritable bowel syndrome (IBS) and IBD are frequently mistaken, however they are not the same illness. IBS is a syndrome that designates a collection of gastrointestinal symptoms, such as cramping or diarrhea. Although it can be quite painful and have an impact on quality of life, IBS doesn't lead to intestinal inflammation or damage.
IBD has the potential to seriously inflame the intestine and harm its walls. IBD affects around 3 million Americans and is on the rise, particularly among non-Hispanic Black adults. A perforated gut wall, which can result in infection and even sepsis, is one complication of inflammatory bowel disease. Sepsis is the body's potentially fatal response to infection, and it was formerly known as blood poisoning.
Sepsis is a medical emergency that calls for prompt diagnosis and treatment, just as heart attacks or strokes. Any infection in the body, such as pneumonia, the flu, or urinary tract infections, can lead to sepsis and septic shock. Sepsis causes one-third of patients to pass away globally. Those who do survive frequently experience life-altering consequences include post-traumatic stress disorder (PTSD), persistent pain, exhaustion, and organ failure.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global inter-alpha-inhibitor proteins market. The pandemic caused numerous clinical trials for novel medications and treatments, including those employing IAIPs, to be canceled or delayed.
Global regulatory organizations changed their objectives in order to hasten the creation and endorsement of COVID-19 medications and vaccines. The regulatory procedures for additional biopharmaceutical products, such as medicines based on IAIP, may have slowed considerably as a result.
By Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Others
By Molecule Type
• Peptides
• Polymer
• Small molecule
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Merck KGaA, ProThera Biologics, Inc., Takeda Pharmaceutical Company Limited, ProMetic Life Sciences Inc. and others.
Why Purchase the Report?
• To visualize the global Inter-alpha-inhibitor proteins market segmentation based on product type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of inter-alpha-inhibitor proteins market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global inter-alpha-inhibitor proteins market report would provide approximately 38 tables, 43 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Phases
3.2. Snippet by Molecule Type
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Focus on Inflammatory Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Limited Clinical Data
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Phases
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phases
7.1.2. Market Attractiveness Index, By Phases
7.2. Late-stage products (Phase III)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Mid-stage products (Phase II)
7.4. Early-stage product (Phase I)
7.5. Others
8. By Molecule Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
8.1.2. Market Attractiveness Index, By Molecule Type
8.2. Peptides*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Polymer
8.4. Small molecule
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phases
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phases
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phases
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phases
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phases
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Merck KGaA*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. ProThera Biologics, Inc.
11.3. Takeda Pharmaceutical Company Limited
11.4. ProMetic Life Sciences Inc.
11.5. Others
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us